Feature | June 22, 2012

FDA Panel Does Not Recommend New ACS Indication for Xarelto

Janssen said it will work with FDA to address issues for its use in acute coronary syndromes

June 22, 2012 — The the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee voted in May against recommending approval of expanding the indication for rivaroxaban (Xarelto).  The drug’s maker, Janssen Research and Development LLC, wants to expand the indication to include the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS). The FDA recently issued a response letter regarding the drug’s supplemental new drug application (sNDA), which the company is evaluating and said it will address the agency's questions.

Xarelto is approved for three clinical uses in the United States: To reduce the risk of blood clots in the legs and lungs of people who have just had knee replacement surgery, to reduce this risk in people who have just had hip replacement surgery and to reduce the risk of both hemorrhagic and thrombotic strokes as well as other blood clots in people with atrial fibrillation not caused by a heart valve problem. Janssen submitted this sNDA in December 2011 and received a priority review designation from the FDA in February.

Healthcare market research firm Decision Resources recently surveyed U.S. cardiologists and managed care organization (MCO) pharmacy directors. Respondents said reducing the incidence of mortality is the greatest unmet need in post-myocardial infarction and Xarelto is being watched as a possible pharmaceutical solution. 

“Despite the declining rate of deaths due to myocardial infarction and despite the emergence of novel antiplatelet agents and optimal statin therapy, the incidence of mortality remains the attribute that most influences surveyed cardiologists’ prescribing decisions in post-myocardial infarction,” said Decision Resources analyst Conor Walsh, Ph.D. “According to clinical data and thought leaders we interviewed, Bayer/Janssen’s Xarelto has demonstrated the potential to significantly fulfill this unmet need.”

For more information: www.janssenrnd.com

Related Content

News | Business| February 09, 2016
February 9, 2016 — Cigna has entered into an...
ACC late breakers
News | ACC| February 09, 2016
February 9, 2016 — The late-breaking clinical trial presentations have been announced for the 2016 American College o
Watchman, left atrial appendage closure, LAA occluder
Technology | Left Atrial Appendage (LAA) Occluders| February 09, 2016
February 9, 2016 — Boston Scientific Corp.
volanesorsen

Figure 1: This illustrates how volanesorsen works to prevent the formation of apoC-III protein

 

Feature | Pharmaceuticals| January 22, 2016 | Rosanne M. Crooke, Ph.D.
Familial chylomicronemia syndrome (FCS) is a rare, genetic disease characterized by mutations in genes affecting the
Feature | Genetic Testing| December 22, 2015 | Kevin P. Greene, M.D.
Statins are lifesaving medications — they have been shown to greatly reduce heart attack and other related events by

Photo courtesy of Vital Images

News | ACC| December 22, 2015
December 22, 2015 — In 2015, results from the ITALIC and CvLPRIT trials, along with studies examining lifestyle facto
ROCKET AF, executive committee, secondary analysis, rivaroxaban, FDA recall
News | Antiplatelet and Anticoagulation Therapies| December 17, 2015
The ROCKET AF Clinical Trial Executive Committee announced its secondary analysis of the phase III trial (ROCKET AF) of...
Overlay Init